Protara net loss widens to $21.7 million in Q2 FY26; R&D expenses rise to $17 million
TARA•Pipeline timelines and enrollment updates
Protara expects to complete enrollment in the ADVANCED-2 BCG-unresponsive cohort in 4Q 2026, while redesigning ADVANCED-3 as an exploratory NMIBC trial.
It expects a STARBORN-1 update and to complete enrollment in 4Q 2026, targets a TARA-002 lymphatic malformations BLA in 2H 2027, and sees THRIVE-3 interim data in 4Q 2026.
Second-quarter loss widens as R&D spending rises
Protara posted a 2Q 2026 net loss of $21.7 million, widening from $15 million a year earlier; loss per share was $0.36.
R&D spending climbed 57.41% to $17 million, due to higher clinical-trial costs, personnel expenses and chemistry, manufacturing and controls work.
G&A expenses rose 10.15% to ; cash, cash equivalents and marketable debt securities totaled at June 30.
